Acute Heart Failure
Natriuresis-guided diuretic therapy in acute heart failure
On-site diagnostics enable effective personalized medicine.
![](https://cdn.prod.website-files.com/65ca1193a3f9de8456b98e36/65ce47fe949d8613a960938c_lab-pieter.webp)
![](https://cdn.prod.website-files.com/65ca1193a3f9de8456b98e36/669510ab1f44a314fd252a5c_urimoni-visual.png)
The opportunity
On-site diagnosis and treatment monitoring
Acute Heart Failure (AHF) is a critical condition that requires urgent medical attention and continuous close monitoring, especially for elderly people. With symptoms ranging from breathlessness and fatigue to high jugular venous pressure and low urine output, AHF requires immediate evaluation and treatment. Approximately one million patients in Europe are hospitalized for AHF each year, requiring frequent and accurate monitoring of urinary biomarkers to guide diuretic therapy and prevent further deterioration. Current methods, which involve infrequent and delayed urine testing, often fail to reflect real-time patient conditions, leading to suboptimal treatment adjustments and increased risk of mortality and rehospitalization.
This approach facilitates early detection of poor diuretic response, allowing timely and precise adjustments to treatment plans, thereby minimizing the risk of kidney damage and improving patient outcomes. With approximately 1.73 million AHF hospitalizations annually in key markets, there is a significant opportunity to improve patient care and reduce mortality rates through the adoption of advanced urine monitoring technologies.
The solution
UriMoni™ for acute heart failure
Healthcare professionals agree that continuous monitoring of urinary sodium and urine output is necessary to optimize the treatment and management of patients with Acute Heart Failure (AHF). A non-invasive device such as UriMoni™, attached to the catheter and connected to the Electronic Health Record (EHR), can provide rapid, real-time results, reducing the need for guesswork and improving decision making. This enables early observation of diuretic response, allowing timely adjustment of medical interventions and prevention of further damage.
UriMoni™ facilitates rapid assessment of AHF patients' responses to diuretics through frequent urine monitoring. This accuracy allows healthcare professionals to precisely adjust diuretic dosages to ensure maximum decongestion during the critical first 24-48 hours and to reduce stress on the patient's body. By identifying treatment responses early, UriMoni™ helps prevent avoidable heart failure exacerbations and streamlines the management of AHF patients, enabling healthcare providers to make data-driven decisions.
![](https://cdn.prod.website-files.com/65ca1193a3f9de8456b98e36/65e98c72334b29c2409a82d7_Paramedir98439.webp)